Abstract. Studies have highlighted important features of the nucleocytoplasmic transport of mRNAs and proteins. Nuclear RNA export factor 3 (NXF3) is a member of the nuclear RNA export factor family that plays a role in mediating the export of cellular mRNA from the nucleus to the cytoplasm for translation. However, little is known about the clinical significance of NXF3 in human tumors. To evaluate the prognostic significance of NXF3 in hepatocellular carcinoma (HCC), the expression levels of NXF3 in a cohort of 112 patients with primary HCC who had undergone hepatectomy for histologically confirmed HCC were assessed by immunohistochemistry. It was identified that the expression levels of NXF3 were higher in the primary HCC tissues compared with those in paired peritumoral liver tissues. The overexpression of NXF3 in the HCC tissues was correlated with decreased survival time [hazard ratio (HR) = 1.954, 95% confidence interval (CI) = 1.034-3.695, P=0.039] and earlier tumor recurrence (HR = 2.101, 95% CI = 1.186-3.722, P=0.011) in postoperative patients with HCC. Notably, overexpression of NXF3 was correlated with a poor survival time and increased recurrence following HCC resection in male patients (P=0.020 and P=0.007, respectively) but not in female patients (P=0.916 and P=0.821, respectively). In conclusion, the findings provide evidence that implicates NXF3 as a prospective predictor of HCC prognosis as well as a potential therapeutic target for cancer treatment.

Introduction

Hepatocellular carcinoma (HCC) is the second most common cause of male cancer-related mortalities worldwide, with ~700,000 cancer mortalities due to HCC were reported in 2008 (1). Despite progress in early diagnosis and surgical interventions, the long-term survival rate of patients with HCC remains unsatisfactory due to the high rate of recurrence and metastasis (2). Thus, it is important to explore prognostic factors for HCC and to develop effective therapeutic schemes.

Studies have highlighted important features of the nucleocytoplasmic transport of RNAs and proteins (3). A number of the transport factors have been demonstrated to be dysregulated in primary tumor specimens and linked to poor prognosis (4,5). Nuclear RNA export factor 3 (NXF3) is a member of the nuclear RNA export factor (NXF) family of proteins, which plays a role in mediating the export of cellular mRNA from the nucleus to the cytoplasm for translation (6). NXF3 has been identified as a nucleocytoplasmic shuttle protein and demonstrated to induce RNA export by recruitment of Crm1, which is overexpressed in various types of human cancer (6,7). A study has shown that NXF3 may mediate the downregulation of the levels of transforming growth factor β3 (TGF-β3) mRNA expression and protein secretion in Sertoli cells (8), and TGF-β3 is considered to be involved in tumor progression (9). However, the roles of NXF3 in human tumor development and/or progression remain undetermined and no association between NXF3 and the clinical significance of tumors has been established. In the present study, the expression levels and the clinical relevance of NXF3 were investigated in a cohort of 112 patients with primary HCC. To the best of our knowledge, this is the first time such a study has been conducted. The aim was to establish the association between NXF3 and HCC and identify novel prognostic factors for HCC.

Materials and methods

Study population. Immunohistochemistry (IHC) was performed on tumor and peritumoral tissue samples from 112 patients who had undergone curative resection for HCC at Zhongshan Hospital, Fudan University (Shanghai, China) between February and September 2005. All patients without
distant metastasis or any form of anticancer treatment prior to the surgical resection were selected on the basis of complete clinicopathological and follow-up data for the patients. The clinical typing of tumors followed the tumor-node-metastasis (TNM) classification system of the American Joint Committee on Cancer and the Union for International Cancer Control (7th edition) (10). The histological grade of tumor differentiation was assigned using the Edmondson grading system (11). Ethical approval was obtained from the Zhongshan Hospital Research Ethics Committee and written informed consent was obtained from all patients.

Follow-up after surgery. Patient follow-up was completed in March, 2010 with a median observation time of 48.7 months. A diagnosis of recurrence was based on the typical imaging appearance of hepatic lesions in computed tomography and/or magnetic resonance imaging scans at elevated α-fetoprotein (AFP) levels. The overall survival (OS) time was defined as the interval between surgery and when the patient succumbed to the disease or between surgery and the last observation for surviving patients. Time to recurrence (TTR) was defined as the interval between the date of surgery and that of recurrence. The data were censored at the last follow-up for living patients and patients without any sign of recurrence.

Evaluation of immunohistochemical findings. Tissue sections (4 μm) were stained with hematoxylin and eosin for histological analysis and with specific primary anti-human antibodies against NXF3 (1:150; LS-C31687; LifeSpan Biosciences, Inc., Seattle, WA, USA) for IHC. Following microwave antigen retrieval, the tissues were incubated with the primary antibodies overnight at 4°C followed by a 30-min incubation with the secondary antibody (Dako EnVision kit, Dako, Glostrup, Denmark). The reaction was visualized with diaminobenzidine and the tissues were counterstained with hematoxylin.

The tissue sections were viewed at x200 magnification using a Leica DMi6000B inverted microscope (Leica Microsystems, Heidelberg, Germany) and images were captured. Two experienced pathologists independently assessed all IHC staining. The scoring for nuclear NXF3 expression was based on the staining proportion and intensity. The staining proportion was scored as follows: 0-25% staining, 1; 26-50% staining, 2; 51-75% staining, 3; and 76-100% staining, 4. The staining intensity was scored as follows: Negative intensity, 0; weakly positive, 1; moderately positive, 2; and strongly positive, 3, according to a previous study (12). The sum of the proportion and intensity scores was used to calculate the final staining score, which was then categorized as low (1-5) or high (6-7).

Statistical analysis. Statistical analysis was performed with SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The cumulative survival time was calculated using the Kaplan-Meier method and analyzed with the log-rank test. Univariate and multivariate analyses were performed based on the Cox proportional hazards regression model. The Student's t-test and χ² test were used as appropriate. P<0.05 was considered to indicate a statistically significant difference.

Results

NXF3 expression in HCC tissues. NXF3 staining was mainly observed in the nucleus of the tumor cells. Significantly higher expression levels of NXF3 were identified in the HCC tissues.
compared with those in the paired peritumoral liver tissues, with intense expression of NXF3 in the cancerous tissues and weak expression in the normal liver tissues (P<0.001, Fig. 1).

Clinical relevance of NXF3 expression in HCC. Table I summarizes the clinicopathological data of the patients in the present study. The one-, three- and five-year overall and recurrence-free survival rates of the 112 patients were 81.2, 53.9 and 47.2% and 69.3, 42.6 and 35%, respectively.

Table I. Summary of the clinicopathological data of the 112 patients in the NXF3 protein expression study.

| Variable                  | Cases, n (%) |
|---------------------------|--------------|
| Gender                    |              |
| Male                      | 96 (85.7)    |
| Female                    | 16 (14.3)    |
| Age (years)               |              |
| ≤51                       | 58 (51.8)    |
| >51                       | 54 (48.2)    |
| HBsAg                     |              |
| Negative                  | 13 (11.6)    |
| Positive                  | 99 (88.4)    |
| AFP (ng/ml)               |              |
| ≤20                       | 42 (37.5)    |
| >20                       | 70 (62.5)    |
| GGT (U/l)                 |              |
| ≤54                       | 56 (50)      |
| >54                       | 56 (50)      |
| Liver cirrhosis           |              |
| No                        | 19 (17.0)    |
| Yes                       | 93 (83.0)    |
| Tumor size (cm)           |              |
| ≤5                        | 55 (49.1)    |
| >5                        | 57 (50.9)    |
| Tumor number              |              |
| Single                    | 100 (89.3)   |
| Multiple                  | 12 (10.7)    |
| Tumor encapsulation       |              |
| Complete                  | 72 (64.3)    |
| None                      | 40 (35.7)    |
| Tumor differentiation     |              |
| I-II                      | 84 (75.0)    |
| III-IV                    | 28 (25.0)    |
| Vascular invasion         |              |
| No                        | 69 (61.6)    |
| Yes                       | 43 (38.4)    |
| TNM stage\(^a\)           |              |
| I                         | 61 (54.5)    |
| II-III                    | 51 (45.5)    |
| NXF3 expression           |              |
| Low                       | 34 (30.4)    |
| High                      | 78 (69.6)    |

\(^a\)The clinical typing of tumors followed the TNM classification system of the American Joint Committee on Cancer and the Union for International Cancer Control (edition 7). NXF3, nuclear RNA export factor 3; HBsAg, hepatitis B surface antigen; AFP, \(\alpha\)-fetoprotein; GGT, \(\gamma\)-glutamyltransferase; TNM, tumor-node-metastasis.

High expression levels of NXF3 in the HCC tissues were prevalent in the patients, and were observed in 78 (~70%) of the total 112 patients (Table I).

The proteins of the NXF family play roles in the transport of mRNAs from the nucleus to the cytoplasm, which is fundamental for gene expression (13). Yang et al (6) demonstrated that the expression of NXF3 was tissue-specific, that NXF3 was detected at high levels in the testes and that the RNA export induced by NXF3 could be inhibited by leptomycin B (an antibiotic that specifically blocks Crm1 function), indicating that NXF3 is an adapter for Crm1-dependent nuclear mRNA export. Although Crm1 is overexpressed in various types of human cancer, including glioma, cervical cancer and renal cell carcinoma, and has the potential to be a prognostic

Discussion

The proteins of the NXF family play roles in the transport of mRNAs from the nucleus to the cytoplasm, which is fundamental for gene expression (13). Yang et al (6) demonstrated that the expression of NXF3 was tissue-specific, that NXF3 was detected at high levels in the testes and that the RNA export induced by NXF3 could be inhibited by leptomycin B (an antibiotic that specifically blocks Crm1 function), indicating that NXF3 is an adapter for Crm1-dependent nuclear mRNA export. Although Crm1 is overexpressed in various types of human cancer, including glioma, cervical cancer and renal cell carcinoma, and has the potential to be a prognostic
Table II. Univariate analyses of factors associated with HCC survival and recurrence.

| Variable                                      | OS HR | 95% CI    | P-value | TTR HR | 95% CI    | P-value |
|-----------------------------------------------|-------|-----------|---------|--------|-----------|---------|
| Age (years; ≤51 vs. >51)                      | 1.185 | 0.707-1.984 | 0.520   | 1.392  | 0.871-2.224 | 0.166   |
| Gender (female vs. male)                      | 0.909 | 0.446-1.850 | 0.791   | 0.996  | 0.510-1.944 | 0.990   |
| HBsAg (negative vs. positive)                 | 1.106 | 0.475-2.576 | 0.816   | 1.055  | 0.506-2.202 | 0.886   |
| AFP (ng/ml; ≤20 vs. >20)                      | 2.520 | 1.397-4.546 | 0.002   | 2.385  | 1.418-4.010 | 0.001   |
| GGT (U/l; ≤54 vs. >54)                        | 2.362 | 1.380-4.042 | 0.002   | 2.400  | 1.481-3.889 | <0.001  |
| Liver cirrhosis (no vs. yes)                  | 1.683 | 0.764-3.710 | 0.196   | 1.750  | 0.869-3.523 | 0.117   |
| Tumor size (cm; ≤5 vs. >5)                    | 1.766 | 1.042-2.993 | 0.034   | 1.615  | 1.006-2.593 | 0.047   |
| Tumor number (single vs. multiple)            | 1.127 | 0.511-2.485 | 0.767   | 1.405  | 0.697-2.832 | 0.342   |
| Tumor encapsulation (complete vs. none)       | 1.207 | 0.685-2.126 | 0.514   | 1.366  | 0.854-2.208 | 0.203   |
| Tumor differentiation (I-II vs. III-IV)        | 1.865 | 1.111-3.131 | 0.018   | 1.263  | 0.758-2.105 | 0.370   |
| Vascular invasion (no vs. yes)                | 2.112 | 1.260-3.540 | 0.005   | 1.586  | 0.992-2.537 | 0.054   |
| TNM stage (I vs. II-III)                      | 2.201 | 1.307-3.707 | 0.003   | 1.892  | 1.185-3.021 | 0.008   |
| Intratumoral NXF3 (low vs. high)              | 1.954 | 1.034-3.695 | 0.039   | 2.101  | 1.186-3.722 | 0.011   |

Univariate analysis, Cox proportional hazards regression model. HCC, hepatocellular carcinoma; OS, overall survival time; TTR, time to recurrence; HR, hazard ratio; CI, confidence interval; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; GGT, γ-glutamyltransferase; TNM, tumor-node-metastasis; NXF3, nuclear RNA export factor 3.

Figure 2. Kaplan-Meier analysis of the survival of patients with high or low intratumoral levels of NXF3. (A and B) Patients with high intratumoral levels of NXF3 had a poorer OS time or TTR than the patients with low intratumoral levels of NXF3. (C and D) High intratumoral levels of NXF3 were associated with a poor prognosis for OS time and TTR in male cases. NXF3, nuclear RNA export factor 3; OS, overall survival; TTR, time to recurrence.
marker for cancer (14-16), the clinical relevance of NXF3 in human cancer remains undetermined. In the present study, the data revealed that NXF3 expression levels were markedly elevated in primary human HCC tissues compared with those in peritumoral liver tissues. Furthermore, the clinically relevant data presented showed that patients with HCC and high tumor NXF3 expression levels had decreased OS times and earlier TTR compared with those of patients with low tumor NXF3 expression levels. These data indicate that NXF3 protein expression may be a promising prognostic biomarker for HCC and raises the possibility that NXF3 may play a role in promoting the transformation of hepatocytes to tumor cells, possibly by mediating the dysregulation of nucleocytoplasmic transport.

Additionally, NXF3 expression levels showed prognostic value in male patients with HCC but not in female ones. This finding may be due to the human X chromosome having the property that one X chromosome undergoes inactivation in females (17,18). This feature leads to a genetic situation unique to females in which mutations in oncogenes (possibly including NXF3) or tumor suppressor genes on the inactive chromosome are not expressed. As males have only one materially inherited X chromosome, they are expected to be more susceptible to oncogenic alterations on the X chromosomes inherited from their mothers (19). Epidemiological data have revealed that the incidence of HCC shows a gender discrepancy, with males accounting for more than two-thirds of HCC cases worldwide (20,21). The factors that contribute to this gender discrepancy remain unclear. Sex hormones and environmental factors are considered to be important in the gender discrepancy in the process of hepatocarcinogenesis (22), while the present study indicates that the X-linked genes (based on data of NXF3) may also play a role in this gender discrepancy.

Nucleocytoplasmic transport maintains the balance of spatial regulation of protein activity and thus is critical for normal cell function (23). The transport of oncogenes and tumor suppressors is disrupted in various types of cancer cells. The forkhead box O (FOXO) transcription factors, including FOXO1a, FOXO3a and FOXO4, are located in the cell nucleus and negatively regulate cell growth, proliferation, differentiation and survival (24). The inactivation of these factors may be induced by inappropriate nuclear export and cytoplasmic mislocalization that is mediated by Crm1 and contributes to the development of glioblastoma multiforme, renal cancer and colon cancer (23,25). Any change in the subcellular localization of oncoproteins and tumor suppressors has the potential to affect the regulation and activity of FOXO transcription factors. Based on the theory that a variety of vital proteins are mislocalized in cancer cells, strategies for redirecting these proteins to the correct subcellular location may be developed to provide effective cancer therapies (26). Therefore, such factors (including Crm1 and NXF3) that are involved in RNA or protein export may yield novel therapeutic targets for cancer treatment.

Although a number of target proteins, including p53, p21, FOXO and NF-xB, have been identified that undergo nuclear export in a Crm1-dependent manner (27), few mRNAs or proteins for NXF3-dependent nuclear export have been identified thus far. A study has shown that NXF3 mediates the downregulation of the levels of TGF-β3 mRNA expression and protein secretion in Sertoli cells (8), but additional studies are required to confirm whether TGF-β3, which is considered to be involved in tumor progression, may be a candidate target gene mediated by NXF3-dependent nuclear export. In the present study, the findings provide a preliminary connection between NXF3 expression levels and HCC. Further studies are required to identify the specific mRNAs or proteins for NXF3-dependent nuclear export and to establish the exact role of NXF3 in the pathogenesis of HCC.

In summary, NXF3, as an NXF family member, has for the first time, to the best of our knowledge, been demonstrated
to be linked to human cancer, extending its role into tumor development. Furthermore, NXF3 was identified to be correlated with the overall and recurrence-free survival time in postoperative patients with HCC, suggesting that NXF3 may be a promising prognostic marker for HCC as well as a novel RNA export pathway for targeting with cancer therapies.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (nos. 30872503 and 81071992).

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62: 394-399, 2012.
3. Grünwald D, Singer RH and Rout M: Nuclear export dynamics of RNA-protein complexes. Nature 475: 333-341, 2011.
4. Siddiqui N and Borden KL: mRNA export and cancer. Wiley Interdiscip Rev RNA 3: 13-25, 2012.
5. Chow KH, Factor RE and Ullman KS: The nuclear envelope environment and its cancer connections. Nat Rev Cancer 12: 196-209, 2012.
6. Yang J, Bogerd HP, Wang PJ, Page DC and Cullen BR: Two closely related human nuclear export factors utilize entirely distinct export pathways. Mol Cell 8: 397-406, 2001.
7. van der Watt PJ and Leaner VD: The nuclear exporter, Crm1, is regulated by NFy and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta 1809: 316-326, 2011.
8. Yin Y, Wang G, Liang N, et al: Nuclear export factor 3 is involved in regulating the expression of TGF-beta3 in an mRNA export activity-independent manner in mouse Sertoli cells. Biochem J 452: 67-78, 2013.
9. Petrella BL, Armstrong DA and Vincenti MP: Interleukin-1 beta and transforming growth factor-beta 3 cooperate to activate matrix metalloproteinase expression and invasiveness in A549 lung adenocarcinoma cells. Cancer Lett 325: 220-226, 2012.
10. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
11. Edmondson HA and PE Steiner: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503, 1954.
12. Ke AW, Shi GM, Zhou J, et al: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49: 491-503, 2009.
13. Cullen BR: Nuclear mRNA export: insights from virology. Trends Biochem Sci 28: 419-24, 2003.
14. Shen A, Wang Y, Zhao Y, Zou L, Sun L and Cheng C: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65: 153-160, 2009.
15. van der Watt PJ, Maske CP, Hendricks DT, et al: The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124: 1829-1840, 2009.
16. Inoue H, Kauffman M, Shacham S, et al: CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 189: 2317-2326, 2013.
17. Lyon MF: Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190: 372-373, 1961.
18. Lyon MF: Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet 14: 135-148, 1962.
19. Spatz A, Borg C and Feunteun J: X-chromosome genetics and human cancer. Nat Rev Cancer 4: 617-629, 2004.
20. Chen JG and Zhang SW: Liver cancer epidemic in China: past, present and future. Semin Cancer Biol 21: 59-69, 2011.
21. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
22. Wang N, Zheng Y, Yu X, Lin W, Chen Y and Jiang Q: Sex-modified effect of hepatitis B virus infection on mortality from primary liver cancer. Am J Epidemiol 169: 990-995, 2009.
23. Kau TR, Way JC and Silver PA: Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4: 106-117, 2004.
24. van der Horst A and Burgering BM: Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 8: 440-450, 2007.
25. Kau TR, Schroeder F, Ramaswamy S, et al: A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 4: 463-476, 2003.
26. Sakakibara K, Saito N, Sato T, et al: CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118: 3922-3931, 2011.
27. Mao L and Yang Y: Targeting the nuclear transport machinery by rational drug design. Curr Pharm Des 19: 2318-2325, 2013.